Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Isoxsuprine API Manufacturers & Suppliers
2 verified results
Commercial-scale Suppliers
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Isoxsuprine | CAS No: 395-28-8 | GMP-certified suppliers
A medication that relaxes uterine and vascular smooth muscle to manage peripheral vascular disease and suppress premature labor through vasodilation and muscle relaxation effects.
Therapeutic categories
Product Snapshot
- Isoxsuprine is available as oral tablets and injectable formulations
- It is primarily used for vasodilatory purposes in therapeutic applications
- The product has FDA approval history in the US but has faced withdrawal in certain indications
Clinical Overview
Clinically, isoxsuprine has been utilized in the management of peripheral vascular disease to improve blood flow and alleviate symptoms associated with compromised circulation. It has also seen use as a tocolytic agent aimed at suppressing premature labor by relaxing uterine smooth muscle. Although specific pharmacodynamic and detailed mechanistic data are not fully described, the drug’s actions align with its classification as a beta-adrenergic receptor agonist, facilitating relaxation through adrenergic beta-receptor stimulation.
Isoxsuprine belongs to the chemical class of phenylpropanes, with its molecular structure incorporating a phenylpropane moiety. It is categorized under several pharmacological groups, including adrenergic agents, adrenergic beta-agonists, vasodilators, and reproductive control agents. These classifications reflect its roles in cardiovascular modulation and reproductive system intervention.
Absorption, distribution, metabolism, and excretion (ADME) parameters are not comprehensively documented in available sources. However, the drug’s clinical use demands careful monitoring due to its potential cardiovascular effects, such as inducing tachycardia and alterations in blood pressure, necessitating caution in patients with pre-existing cardiovascular conditions. Safety concerns include possible systemic hypotensive effects and associated reflex tachycardia.
Isoxsuprine’s regulatory status includes both approval and withdrawal in different jurisdictions, reflecting variable clinical adoption and regulatory assessments. Notable branded formulations have existed, although these may differ regionally and by indication.
For API sourcing, it is critical to ensure compliance with stringent quality standards and regulatory requirements. Procurement should focus on suppliers with validated manufacturing processes that guarantee batch-to-batch consistency, impurity profiling, and adherence to relevant pharmacopeial specifications. Given isoxsuprine’s diverse historical usage and variable approval status, verification of documentation supporting the intended market’s regulatory framework is essential.
Identification & chemistry
| Generic name | Isoxsuprine |
|---|---|
| Molecule type | Small molecule |
| CAS | 395-28-8 |
| UNII | R15UI3245N |
| DrugBank ID | DB08941 |
Formulation & handling
- Isoxsuprine is a small molecule suitable for both oral and injectable formulations.
- Due to low water solubility, formulation strategies should address solubility enhancement for optimal bioavailability.
- No peptide or biologic properties are present, indicating standard stability and handling protocols apply.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient (API) has patents expiring in the US during 2025, after which generic formulations are expected to increase market presence. Current products primarily target the US market, where the API is approaching a mature lifecycle phase. |
|---|
| Markets | US |
|---|
Supply Chain
| Supply chain summary | Isoxsuprine is primarily manufactured by a limited number of originator companies with branded products available mainly in the US market. The presence of multiple branded formulations suggests established supply sources in this region. Given the concentration in the US and typical patent timelines, the market likely faces existing or imminent generic competition. |
|---|
Isoxsuprine is a type of Adrenergic agents
Adrenergic agents are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that target the adrenergic system in the body. This system is responsible for regulating various physiological responses, including heart rate, blood pressure, and smooth muscle contraction.
Adrenergic agents can be further divided into two main groups: adrenergic agonists and adrenergic antagonists. Adrenergic agonists stimulate the adrenergic receptors, leading to an increase in sympathetic nervous system activity. This can result in effects such as vasoconstriction, bronchodilation, and increased heart rate. Adrenergic agonists are commonly used in the treatment of conditions such as asthma, hypotension, and cardiac arrest.
On the other hand, adrenergic antagonists block the adrenergic receptors, thereby inhibiting the effects of sympathetic nervous system activation. These agents are often employed to lower blood pressure, treat certain heart conditions, and manage symptoms associated with conditions like benign prostatic hyperplasia. Adrenergic antagonists can be further classified into alpha-adrenergic antagonists and beta-adrenergic antagonists, based on their selectivity for different adrenergic receptor subtypes.
Pharmaceutical companies extensively utilize adrenergic agents as key components in the development of various medications. Adrenergic APIs offer targeted effects on the adrenergic system, allowing for precise modulation of physiological responses. The understanding of adrenergic agents and their mechanisms of action is vital for the design and optimization of drugs used in the treatment of numerous medical conditions. Researchers and scientists continue to explore and innovate within this subcategory to develop new adrenergic agents with enhanced efficacy and fewer side effects, ultimately improving patient outcomes.
Isoxsuprine (Adrenergic agents), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
Isoxsuprine API manufacturers & distributors
Compare qualified Isoxsuprine API suppliers worldwide. We currently have 2 companies offering Isoxsuprine API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Aquatic Remedies Pvt Ltd | Producer | India | India | CoA | 35 products |
| Unnati Pharmaceuticals Pv... | Distributor | India | India | CoA | 70 products |
When sending a request, specify which Isoxsuprine API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Isoxsuprine API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
